AMXI 2001
Alternative Names: AMXI-2001Latest Information Update: 28 Apr 2025
At a glance
- Originator AtlasMedx
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA damage stimulants; Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Cancer in USA
- 09 Mar 2021 AMXI 2001 is available for licensing as of 09 Mar 2021. https://atlasmedx.com/partnering/